

**PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE -  
RECEIPT OF LISTING AND QUOTATION NOTICE**

---

**1. INTRODUCTION**

The Board of Directors (the "**Board**" or "**Directors**") of iX Biopharma Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**"), refers to the announcement dated 6 June 2024 ("**Rights Issue Announcement**") on the renounceable non-underwritten rights issue (the "**Rights cum Warrants Issue**") of up to 172,320,768 new ordinary shares in the capital of the Company (the "**Rights Shares**") at an issue price of S\$0.03 (the "**Issue Price**") for each Rights Share, with up to 86,160,384 free detachable and transferable warrants (the "**Warrants**"), with each Warrant carrying the right to subscribe for one (1) new ordinary share in the capital of the Company ("**New Share**") at the exercise price of S\$0.06 for each New Share (the "**Exercise Price**"), on the basis of 11 Rights Shares for every 50 existing ordinary shares in the capital of the Company (the "**Shares**") held by Entitled Shareholders (as defined below) as at a date and time to be determined by the Board (the "**Record Date**") for the purpose of determining the entitlements of the Entitled Shareholders under the Rights cum Warrants Issue, fractional entitlements to be disregarded, and one (1) Warrant for every two (2) Rights Shares subscribed.

Unless otherwise defined herein, all capitalised terms shall have the meaning ascribed to them in the Rights Issue Announcement.

**2. RECEIPT OF LISTING AND QUOTATION NOTICE**

Further to the Rights Issue Announcement, the Board is pleased to announce that the Company has, on 10 June 2024, received in-principle approval ("**LQN Notice**") from the SGX-ST for the listing and quotation of the Rights Shares, the Warrants, the New Shares, and up to 4,151,404 Shares arising from the adjustment of the Conversion Price of the Bonds assuming the Bonds are not converted and the conversion price is adjusted as a result of the Rights cum Warrants Issue ("**Additional Conversion Shares**") on the Catalist, subject to the following conditions:

- (a) the Company's compliance with the SGX-ST's listing requirements;
- (b) the Company making an announcement on the details of the adjustment to the minimum conversion price and additional conversion shares of the Bonds as a result of the Rights cum Warrants Issue ("**Adjustment Details**"); and
- (c) submission of confirmation that a sufficient spread in the Warrants as required under Rule 826 of the Catalist Rules is complied with.

Please note that the LQN Notice is not an indication of the merits of the Rights cum Warrants Issue, the Rights Shares, the Warrants, the Additional Conversion Shares, the Company and/or its subsidiaries.

**3. CAUTIONARY STATEMENT**

Shareholders and potential investors are advised to exercise caution when dealing or trading in the Shares as there is no certainty or assurance that the Rights cum Warrants Issue will be completed or that no changes will be made to the terms thereof. Shareholders and potential investors are also advised to read this Announcement and any further announcements by the Company carefully, and where in doubt as to the action that they should take, they should consult their financial, tax or other professional adviser immediately.

#### **4. FURTHER ANNOUNCEMENTS**

The Company will make further announcements relating to the Rights cum Warrants Issue as may be necessary or appropriate from time to time, including an announcement on the Adjustment Details and the Record Date.

#### **IX BIOPHARMA LTD. BY ORDER OF THE BOARD**

Eddy Lee Yip Hang  
Chairman & CEO  
11 June 2024

---

This announcement has been reviewed by the Company's Sponsor.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881